Spironolactone Use Does Not Increase the Risk of Estrogen-Dependent Cancer Recurrence: A Retrospective Analysis

    Shane Chapman, Adam Friedman, Patawut Bovonratwet, Alex Gu, Gaby Moawad
    Image
    Studysummary This study investigated the use of spironolactone in patients with estrogen-dependent cancers, aiming to determine if it is linked to increased cancer recurrence risk, but results are not reported.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Discuss this study in the Community →